全文获取类型
收费全文 | 3242篇 |
免费 | 116篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 22篇 |
儿科学 | 146篇 |
妇产科学 | 33篇 |
基础医学 | 461篇 |
口腔科学 | 35篇 |
临床医学 | 166篇 |
内科学 | 894篇 |
皮肤病学 | 40篇 |
神经病学 | 249篇 |
特种医学 | 84篇 |
外科学 | 528篇 |
综合类 | 12篇 |
预防医学 | 89篇 |
眼科学 | 32篇 |
药学 | 166篇 |
中国医学 | 14篇 |
肿瘤学 | 399篇 |
出版年
2023年 | 10篇 |
2022年 | 9篇 |
2021年 | 38篇 |
2020年 | 23篇 |
2019年 | 45篇 |
2018年 | 45篇 |
2017年 | 31篇 |
2016年 | 38篇 |
2015年 | 59篇 |
2014年 | 88篇 |
2013年 | 129篇 |
2012年 | 185篇 |
2011年 | 216篇 |
2010年 | 118篇 |
2009年 | 115篇 |
2008年 | 221篇 |
2007年 | 241篇 |
2006年 | 245篇 |
2005年 | 261篇 |
2004年 | 233篇 |
2003年 | 224篇 |
2002年 | 253篇 |
2001年 | 42篇 |
2000年 | 25篇 |
1999年 | 45篇 |
1998年 | 56篇 |
1997年 | 44篇 |
1996年 | 40篇 |
1995年 | 46篇 |
1994年 | 37篇 |
1993年 | 27篇 |
1992年 | 17篇 |
1991年 | 26篇 |
1990年 | 9篇 |
1989年 | 18篇 |
1988年 | 12篇 |
1987年 | 14篇 |
1986年 | 8篇 |
1985年 | 10篇 |
1984年 | 10篇 |
1983年 | 8篇 |
1982年 | 8篇 |
1981年 | 10篇 |
1980年 | 8篇 |
1979年 | 5篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1974年 | 4篇 |
1925年 | 1篇 |
1923年 | 3篇 |
排序方式: 共有3370条查询结果,搜索用时 921 毫秒
101.
102.
Ken Arai Shinji Koba Yuya Yokota Fumiyoshi Tsunoda Hiroaki Tsujita Seita Kondo Shigeto Tsukamoto Makoto Shoji Toshiro Shinke 《Journal of atherosclerosis and thrombosis》2020,27(11):1216
Aims: We evaluated the relationship between the ratios of eicosapentaenoic acid and arachidonic acid (EPA/AA), docosahexaenoic acid (DHA)/AA, and delta-5 desaturase activity (D5D) and atherogenic lipid profiles (ALP) and coronary atherosclerosis.Methods: Polyunsaturated fatty acids (PUFA) and ALP were assessed in 436 men with the first episode of acute coronary syndrome (ACS) not take any lipid-lowering drugs. D5D was estimated as the ratio of AA to dihomogamma-linolenic acid (DGLA). These biomarkers were compared between the lower and higher levels of EPA/AA (0.41) or DHA/AA (0.93) according to the levels in Japanese general population. The thrombolysis in myocardial infarction flow (TIMI) grade of the culprit coronary artery was visually estimated during the initial angiography.Results: Approximately 70% of patients had low EPA/AA or DHA/AA. Serum levels of LDL-cholesterol, apolipoprotein B (apoB), and remnant lipoprotein cholesterol (RL-C) were significantly higher in the low EPA/AA or DHA/AA groups, while those of triglycerides and malondialdehyde-modified LDL (MDA-LDL) were significantly higher in the low EPA/AA group alone. The levels of EPA, EPA/AA, DHA/AA, and HbA1c increased and those of DGLA and apoA1 decreased with increasing number of stenotic vessels. Patients with three stenotic coronary vessels or TIMI grade ≥ 1 had significantly higher EPA levels compared with the others. The levels of LDL-cholesterol, non-HDL-cholesterol, triglycerides, small dense LDL-cholesterol, RL-C, MDA-LDL, apoB, and apoE decreased progressively and those of EPA, DHA, EPA/AA and HDL-cholesterol increased as D5D increased.Conclusions: The EPA/AA is a superior risk marker than DHA/AA in term of correlation with ALP in ACS patients. 相似文献
103.
Hidetomo Nakamoto Xue‐Qing Yu Suhnggwon Kim Hideki Origasa Hongguang Zheng Jianghua Chen Kwon Wook Joo Suchai Sritippayawan Qinkai Chen Hung‐Chun Chen Yoshiharu Tsubakihara Hirofumi Tamai Sang Heon Song Indralingam Vaithilingam Kang Wook Lee Kuo‐Hsiung Shu Stanley Hok‐King Lo Masanao Isono Hajimu Kurumatani Kiyonobu Okada Hiroyuki Kanoh Takashi Kiriyama Shunsuke Yamada Toshiro Fujita 《Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy》2020,24(1):42-55
TRK‐100STP, a sustained‐release preparation of the orally active prostacyclin analogue beraprost sodium, targets renal hypoxia. This study aimed to show the superiority of TRK‐100STP over placebos in patients with chronic kidney disease (with either primary glomerular disease or nephrosclerosis) to determine the recommended dose. CASSIOPEIR (Chronic Renal Failure Asian Study with Oral PGI2 Derivative for Evaluating Improvement of Renal Function) was a randomized, double‐blind, placebo‐controlled study conducted at 160 sites in seven Asia‐Pacific countries and regions. Eligible patients (n = 892) were randomized to TRK‐100STP 120, 240 μg, or placebo for a treatment period of up to 4 years. The primary efficacy endpoint was time to first occurrence of a renal composite: doubling of serum creatinine or occurrence of end‐stage renal disease. No significant differences were observed in composite endpoints between TRK‐100STP and placebo (P = 0.5674). Hazard ratios (95% CI) in the TRK‐100STP 120 and 240 μg vs. placebo groups were 0.98 (0.78, 1.22) and 0.91 (0.72, 1.14), respectively. The overall incidence of adverse events and adverse drug reactions was comparable between treatment arms. 相似文献
104.
Jun Nishikawa Ayumu Hosokawa Hiroshi Mihara Ryuji Hayashi Shigeharu Miwa Tatsuhiko Kane Sohachi Nanjo Takayuki Ando Haruka Fujinami Shinya Kajiura Masami Minemura Toshiro Sugiyama 《Clinical journal of gastroenterology》2014,7(2):155-158
Ulcerative colitis (UC) is associated with a number of extraintestinal manifestations (EIMs) that may affect most organ systems. Among the EIMs, those involving the lung are rare. We report a case of pulmonary involvement and pyoderma gangrenosum in a patient with refractory UC. A chest computed tomography showed multiple nodular infiltrates in bilateral lungs. The patient had no respiratory symptoms. No infectious agents were detected. A transbronchial biopsy specimen showed nonspecific features. Prednisolone was initiated with significant improvement in the patient’s abdominal symptoms and pyoderma gangrenosum. Subsequent imaging after steroid therapy showed improvement of the pulmonary infiltrates. The patient’s abdominal symptoms relapsed when prednisolone was tapered. The patient subsequently received a proctocolectomy. Chest radiographs have shown resolution of pulmonary infiltrates. Because pulmonary involvement follows an independent course and a proctocolectomy may not be protective against a recurrence of pulmonary involvement, a careful follow-up should be continued. 相似文献
105.
Introduction
Intracerebral hemorrhage (ICH) is a major clinical concern with anticoagulation therapy. The effect of a new oral direct FXa inhibitor, edoxaban, was determined in a rat model of ICH and compared with a direct thrombin inhibitor, melagatran, and heparin.Methods
To induce ICH, 0.1 U collagenase type VII was injected into the striatum of male Wistar rats under anesthesia with thiopental or halothane. Immediately after ICH induction, edoxaban, melagatran, or heparin were infused intravenously. Five hours after ICH induction, the brain was removed and ICH size was measured. To estimate the margin of safety, antithrombotic effects were evaluated in a rat venous thrombosis model.Results
Edoxaban at 6 mg/kg/h significantly increased ICH volume (1.8-fold) and prolonged prothrombin time (PT) 2.8-fold compared to the vehicle group. No deaths were observed with edoxaban. Melagatran at 1 mg/kg/h increased ICH volume at 1 mg/kg/h (2.8-fold) with 6.1-fold PT prolongation. At 3 mg/kg/h, all rats died due to severe ICH (3.9-fold). Heparin at both 100 and 500 U/kg/h significantly increased ICH. At 500 U/kg/h, 5 out of 8 rats died. The doses required for 50% inhibition of thrombosis of edoxaban, melagatran, and heparin were 0.045 mg/kg/h, 0.14 mg/kg/h, and 55 U/kg/h, respectively. The safety margins between antithrombotic and ICH exacerbation effects of these anticoagulants were 133, 7.1, and 1.8, respectively.Conclusion
The safety margin of edoxaban was wider than that of melagatran or heparin. These results suggest that edoxaban may be preferable from the perspective of ICH exacerbation risk. 相似文献106.
107.
Fujita M Ando K Kawarazaki H Kawarasaki C Muraoka K Ohtsu H Shimizu H Fujita T 《Hypertension》2012,59(1):105-112
Hypertension is very prevalent in chronic kidney disease and critical for its prognosis. Sympathoexcitation and oxidative stress have been demonstrated to be involved in chronic kidney disease. We have shown previously that sympathoexcitation by brain oxidative stress mediates arterial pressure elevation in the salt-sensitive hypertension model, Dahl salt-sensitive rats. Thus, we investigated whether sympathoexcitation by excessive brain oxidative stress could contribute to arterial pressure elevation in salt-induced chronic kidney disease model rats. Young (3-week-old) male Sprague-Dawley rats were randomly assigned to a uninephrectomy or sham operation and then subjected to either a normal salt (0.5%) or high-salt (8.0%) diet for 4 weeks. The young salt-loaded uninephrectomized rats exhibited sympathoexcitation, hypertension, and renal injury, proteinuria and global glomerulosclerosis together with tubulointerstitial damage. Under urethane anesthesia and artificial ventilation, renal sympathetic nerve activity, arterial pressure, and heart rate decreased to a greater degree in the salt-loaded uninephrectomized rats than in the nonsalt-loaded uninephrectomized rats and the salt-loaded or nonsalt-loaded sham-operated rats, when Tempol, a membrane-permeable superoxide dismutase mimetic, was infused acutely into the lateral cerebral ventricle. Oxidative stress in the hypothalamus, measured by lucigenin chemiluminescence, was also significantly greater. Furthermore, in the salt-loaded uninephrectomized rats, antioxidant treatment with chronic intracerebroventricular Tempol decreased sympathetic nerve activity and arterial pressure, which, in turn, led to a decrease in renal damage. Similar effects were elicited by treatment with oral moxonidine, the central sympatholytic agent. In conclusion, sympathoexcitation by brain oxidative stress may mediate arterial pressure elevation in salt-induced chronic kidney disease. 相似文献
108.
109.
Sakuraba A Sato T Matsukawa H Okamoto S Takaishi H Ogata H Iwao Y Hibi T 《International journal of colorectal disease》2012,27(7):947-952
Purpose
Crohn's disease (CD) commonly recurs after surgery, and a number of patients need repeated surgery, especially smokers and those with repeated surgeries or penetrating disease. Whether infliximab prevents postsurgical recurrence in high-risk CD remains unknown. In the present pilot open-labeled study, we investigated the safety and efficacy of scheduled infliximab, which was started early after surgery, in maintaining remission of CD patients who have undergone multiple surgeries due to penetrating disease.Methods
Eleven patients (nine male, two female; age range, 26–48?years) who had undergone repeated surgeries (median, 4; range, 2–5) for penetrating disease were enrolled. Two to 4?weeks after surgery, the patients were started on intravenous infliximab (5?mg/kg) at an 8-week interval. The primary end points were the proportion of patients in clinical remission at the end of the study, the rate of endoscopic/radiologic remission at 24?months, and the rate of adverse effects.Results
One patient dropped out due to non-compliance, and ten patients were eligible for analysis. Clinical remission was maintained in six of ten patients (60.0%) at the end of the study. At 24?months, four out of ten patients were in endoscopic or radiological remission (40.0%). Two patients experienced adverse effects (18.2%), one of whom elected to withdraw from the study.Conclusion
The findings of no major safety concern and possible clinical benefit in our study suggest that further investigation of infliximab as a treatment for prevention of postsurgical recurrence in high-risk CD is warranted. 相似文献110.